Revium Rx (OTC: RVRC) is a pre-clinical biopharmaceutical company developing lipid-based nanoparticle drug delivery platforms for diseases with limited treatment options. The company has no revenue as of its 10-K filed 2026-03-31, as all product candidates remain in early-stage development and have not yet entered clinical trials in the United States or elsewhere. Its two lead programs target antimicrobial resistance and solid tumors, specifically pancreatic ductal adenocarcinoma. Revium Rx operates through a wholly owned Israeli subsidiary, incorporated in 2020, and is incorporated in Nevada following a conversion from Delaware completed in late 2024. The company was originally incorporated on January 24, 1997 as Fun Cosmetic, Inc., passed through entertainment and beverage operating phases, and ceased beverage manufacturing in 2010 before pivoting to its current nanomedicine focus. It trades on the OTC market.

Revenue model

No revenue as of the 10-K filed 2026-03-31. The company is pre-clinical and pre-revenue. Future monetization pathways disclosed in the filing include milestone payments, royalty payments, and licensing arrangements, all contingent on successful clinical development and regulatory approval.

Products and services

Two lead product candidates: (1) a liposomal formulation targeting antimicrobial resistance, focused on severe or treatment-refractory bacterial infections; (2) Nano-Candesartan, a nanoparticle-based angiotensin receptor blocker (ARB) being evaluated for combination therapy with an initial indication in pancreatic ductal adenocarcinoma (PDAC). Both candidates use lipid-based nanoparticle encapsulation technology designed to improve drug stability, tissue targeting, and controlled release. Neither candidate has been clinically tested as of the filing date.

Customers and end markets

No commercial customers as of the 10-K filed 2026-03-31. Target end markets are hospital-based treatment of antimicrobial-resistant infections and oncology, specifically pancreatic cancer. The company has indicated interest in pursuing Orphan Drug Designation in the United States and Orphan Medicinal Product Designation in the European Union for its oncology program.

Value-chain role

Early-stage drug developer with no internal manufacturing. Relies on CDMOs (Contract Development and Manufacturing Organizations) for development and scale-up of therapeutic candidates. Holds or is pursuing licenses, including a disputed license from Yissum (the technology transfer company of the Hebrew University of Jerusalem) related to Nano-Candesartan.

Geographic exposure

Incorporated in Nevada as of late 2024. Operates through a wholly owned Israeli subsidiary formed June 22, 2020. Regulatory strategy disclosed in the filing includes the U.S. FDA and the European Medicines Agency (EMA).

Competitors

Matinas BioPharma, Encapsula NanoSciences

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations